Rationale: Baseline circulating concentrations of C-reactive protein (CRP) are significantly associated with cardiovascular disease risk in general populations. This modest association has been inappropriately conflated with causality, and it has been claimed that CRP is proatherogenic. Most of the known causative factors for atherosclerosis stimulate increased CRP production, but comprehensive genetic epidemiology studies provide no support for a pathogenic role of CRP. The reported proinflammatory effects of human CRP preparations on healthy cells in vitro and in healthy animals in vivo have all been produced by poorly characterized CRP preparations, demonstrably caused by impurities, or elicited by CRP made in recombinant Escherichia coli not by humans. None of the in vitro or animal findings have been reproduced with pure natural human CRP. Nevertheless, the strong proinflammatory effects of infusing recombinant bacterial CRP into humans have still been inappropriately ascribed to CRP.
I n 1994, we first reported the prognostic association of increased plasma concentration of the sensitive acute phase proteins, C-reactive protein (CRP), and serum amyloid A protein (SAA), with clinical events in patients with acute coronary syndromes. 1 The article triggered an avalanche of interest in the predictive significance of baseline CRP values for coronary and other cardiovascular disease events. As commonly happens in observational epidemiology, the early studies greatly overestimated the significance of the association in the general population. In particular, the actual numbers of cardiovascular events were small even in large studies with many participants, and the results were, therefore, neither reliable nor reproducible. 2, 3 As the scale of these studies increased, it became clear that raised baseline CRP values, that is >3 mg/L, the 90th centile of the distribution in healthy white adults, were only modestly associated with increased risk of cardiovascular disease events, [4] [5] [6] [7] and that most of the association derived from the fact that almost all the known causative risk factors also stimulate the acute phase response. 8, 9 Nevertheless, the pervasive conflation of association and causality led to a flood of controversial claims that CRP is proinflammatory and proatherogenic. This misapprehension persisted, despite the technical flaws underlying these experimental studies and the persistent failure to reproduce them when well-controlled experiments were conducted with well-characterized pure CRP preparations and in rigorous animal experiments. [10] [11] [12] [13] [14] Furthermore, the now substantial genetic epidemiology evidence provides no support at all for a causal relationship between CRP production and cardiovascular disease events. 15 Interestingly, the prognostic association with increased SAA production that we originally reported, 1 and which was as strong as that with CRP, was largely ignored. This was perhaps because SAA is a less stable and tractable analyte for which assays were much less readily available than for CRP, rather than for any objective, evidence-based reason.
The most controversial effect claimed for human CRP is its proinflammatory action when infused into human volunteers and patients. [16] [17] [18] [19] [20] [21] We have previously shown that any such effects on cells in vitro and in mice in vivo are strictly confined to CRP made by recombinant bacteria and are not shown at all by authentic pure human CRP made by humans. 22 Nevertheless, irrefutable resolution of the controversy demands infusion of genuine, natural, pure human CRP into humans. Here, we report this experiment and confirm that there were no detectable proinflammatory or proatherogenic effects, demonstrating unequivocally that the wide range of responses to infusion of recombinant CRP made in Escherichia coli was caused by bacterial products or other contaminants and not by the human CRP molecule itself.
Methods
Authentic natural human CRP was isolated and purified from 38 kg of B+1 paste derived from pooled plasma of US donors undergoing plasmapheresis. The preparation and characterization of this batch of pharmaceutical GMP grade CRP have been reported in comprehensive detail, including its purity, full structural and functional integrity, and lack of detectable endotoxin in solutions at 3 mg/mL of CRP, which is <0.1 EU/mg of CRP. 23 Furthermore, this material has been shown to have no proinflammatory or other adverse effects on human peripheral blood mononuclear cells in vitro or in mice in vivo. 23 The UK Medicines and Healthcare Products Regulatory Agency confirmed that intravenous infusion of this CRP preparation into healthy adult volunteers, according to the protocol reported here, was outside the scope of the Medicines for Human Use (Clinical Trials) Regulations, 2004, the prevailing UK law covering such studies. The study was approved by the Central London REC 1 Research Ethics Committee and the UCL Institutional Review Board. All participants gave fully informed written consent. Full details of the protocol and comprehensive regulatory framework covering all aspects of the study are included in the Online Data Supplement. A single site, dose ascending study was conducted with 7 consecutive participants each receiving a single bolus intravenous infusion of CRP after initial screening and then preinfusion baseline examination and blood sampling, followed by postinfusion examinations and blood samples after 0.5, 4, 8, 24, and 48 hours, 6 and 10 days. Assays for cytokines, interleukin (IL)-1β, IL-6, tumor necrosis factor-α, and IL-10 23,24 were performed on plasma taken at baseline, 4, 8, and 24 hours. The assays were all calibrated with the respective World Health Organization International Standard preparations for each cytokine and spike-recovery assays with control plasma samples were close to 100% for all cytokines. CRP (Roche) and SAA (Siemens) assays, and full routine biochemical and hematologic screening, were performed on all blood samples. Physical examination included measurement of temperature, pulse, and blood pressure at each sampling time, as well as routine 12-lead ECG and enquiry about any self-administered medications.
Results
After the bolus infusion of CRP, there was a clear dose-dependent increase in circulating CRP concentration, peaking in the 30-minute sample in all subjects and reaching 36 and 44 mg/L, respectively, in the 2 individuals who received the top dose of 2 mg/kg. After 30 minutes, the circulating CRP concentrations fell steadily in all subjects, at a rate consistent with the known ≈19-hour plasma half life of human CRP in humans ( Figure 1 ). 25 There was no evidence that infusion of human CRP triggered any new production of CRP. Similarly, none of the present 7 subjects showed any increase beyond the reference range in their circulating concentrations of SAA or any significant change in neutrophil or platelet counts (Figure 2) .
The plasma concentrations of the proinflammatory cytokines, IL-1β, tumor necrosis factor-α, and IL-6 also confirmed that our CRP infusion had no significant effects (Table) . Only in subject 1, who received the lowest dose of CRP, was there any significant apparent rise in just a single cytokine, tumor necrosis factor-α, and at just a single time point. However, the raw optical density data from the 4 replicates of the ELISA assay on this sample were widely variant and included 1 effectively zero value consistent with the zero values in the 3 other samples from this individual, and strongly suggesting that the other readings reflect a technical aberration. Crucially, the circulating SAA values were within the reference range in all samples from all subjects. There was thus no evidence that CRP infusion affected production of any of the cytokines assayed immunochemically or any sign of increased functional proinflammatory cytokine activity in vivo. Values for the anti-inflammatory cytokine, IL-10, were variable, but there was no evidence of any consistent or dose-dependent effect of CRP infusion.
There were no clinically significant changes in any other physical, biochemical, or hematologic parameters monitored in the study, all of which are shown in Tables I to VIII in the Online Data Supplement.
Discussion
In sharp contrast to the persistent and increased CRP production observed by Bisoendial et al [16] [17] [18] [19] [20] [21] after infusion of bacterial recombinant CRP, the CRP values in our subjects declined inexorably at a rate consistent with the normal clearance of human CRP. Infusion of 1.25 mg/kg of bacterial recombinant CRP produced initial peak CRP values of 20.5 to 28.1 mg/L, which fell before rising again to 29.0 mg/L. 16 Here, the infusion of authentic human CRP itself triggered no new production of CRP, and the concept proposed by Bisoendial et al, [16] [17] [18] [19] [20] [21] that autologous human CRP triggers production of more CRP, is not supported by any evidence in the past 83 years of clinical and experimental studies of CRP. 26, 27 Furthermore, none of the present 7 recipients of a range of doses of authentic pharmaceutical-grade human CRP showed any increase in their circulating concentrations of SAA, the most sensitive human acute phase protein. Once again this contrasts sharply with the Bisoendial results in which infusion of bacterial recombinant CRP induced massive acute phase responses of SAA, reaching >2000 mg/L in some subjects, 16 values typically seen in acute sepsis or major trauma.
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Our present subjects also showed no meaningful increase in cytokine production, and there was no evidence for abnormally raised proinflammatory cytokine activity at any stage, with both SAA concentrations and the levels of all other acute phase reactants within the reference range throughout. Indeed there was no significant change in any of the clinical, physical, biochemical, coagulation, or hematologic parameters that were assessed, despite administration of sufficient human CRP to achieve typical circulating acute phase response values.
We have previously discussed in detail the nonspecific method used to isolate the recombinant bacterial CRP 28 used by Bisoendial et al [16] [17] [18] [19] [20] [21] and the fact that the single gel filtration procedure they used to purify the protein before infusion into humans could not possibly have removed the abundant contamination with bacterial material that was demonstrably present. 22 Indeed, despite their failure to detect Figure 2 . Circulating serum amyloid A protein (SAA), neutrophils, and platelets before and after C-reactive protein (CRP) infusion. Values are shown for each individual subject at screening (S) and at baseline (B) immediately before infusion of human CRP and at the times shown after infusion. Subject 1, CRP dose 0.25 mg/kg; subject 2, 0.50 mg/kg; subject 3, 1.00 mg/kg; subject 4, 1.25 mg/kg; subject 5, 1.25 mg/kg; subject 6, 2.00 mg/kg; subject 7, 2.00 mg/kg. The lower limit of detection for all assays was 16 pg/mL. The SEM values were <10% of the means for the all detectable concentrations and are, therefore, not shown. CRP indicates C-reactive protein; IL, interleukin; and TNF, tumor necrosis factor. endotoxin, they themselves report the presence of substantial non-CRP organic material in the CRP preparation they used. In contrast, we have reported in comprehensive detail the purity and full structural and functional integrity of our present pharmaceutical-grade CRP preparation, derived from humans rather than recombinant bacteria. 23 Our present findings thus demonstrate conclusively that intact authentic human CRP itself does not have any detectable proinflammatory effects in normal healthy adult subjects. This result is consistent with the compelling evidence from large-scale observational 6, 7 and genetic epidemiology studies, 15 showing no evidence to support a causative role of CRP in human atherosclerosis. Similarly, robust experimental animal studies also show that CRP does not contribute to atherogenesis. [12] [13] [14] Indeed human CRP rather seems to be antiatherogenic in these models. 13, 14 Nevertheless, it is important to distinguish clearly between the fact that CRP has no proinflammatory effects in healthy subjects and the potential proinflammatory role of human CRP in individuals with pre-existing tissue damage. Human CRP binds avidly to dead and damaged cells in vivo and is a potent activator of the classical complement pathway, via which it can trigger increased inflammation and exacerbate tissue damage. We have demonstrated this effect in rat models of both acute myocardial infarction 29 and stroke, 30 in which peak circulating concentrations of human CRP were provided in the range >100 mg/L typical of significant human acute phase responses. There is much corroborative clinical evidence that the same phenomenon occurs in humans. Therefore, we continue to work on the development of small molecule inhibitors of CRP binding in vivo, for use as drugs to abrogate the adverse, complement-dependent, pathogenic effects of CRP. 31 This potential therapeutic approach is critically based on reproducible experimental and clinical observations with well-established molecular and cellular mechanisms. 29, 31 
